Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Britain says it expects its vaccine contracts to be met

Fri, 29th Jan 2021 08:23

* UK refuses to publish Astra supply details

* Scotland says it will publish vaccine supply data

* EU warns drug companies over supply delays
(Adds UK PM Johnson's spokesman, Scottish health minister)

By Sarah Young and William James

LONDON, Jan 29 (Reuters) - Britain is confident it will
receive sufficient COVID-19 vaccine doses to keep its programme
on track despite a dispute between the European Union and
drugmaker AstraZeneca, Prime Minister Boris Johnson's spokesman
said on Friday.

EU Commission Head Ursula von der Leyen has demanded that
Astrazeneca deliver contracted vaccine supplies from Britain to
EU states, and has dimissed the notion that the United Kingdom
should have first rights to doses produced there.

The EU has warned drug companies that it would use all legal
means or even block exports unless they agreed to deliver shots
as promised.

The bloc published its contract with AstraZeneca on Friday,
which said the Anglo-Swedish drugmaker should use facilities in
Britain as well as continental Europe in its best efforts to
manufacture its vaccines for the EU.

Prime Minister Boris Johnson's spokesman said on Friday the
government would not discuss contractual matters. But he said
the government expected contracts to be "facilitated" and he was
confident of its supply.

"AstraZeneca has clearly stated they will be able to provide
2 million vaccine doses a week and we've said we will get that
to people as quickly as possible," he said.

While Britain is running ahead of its European peers on
vaccinations, with almost 7.5 million receiving their first dose
so far, the British COVID-19 death toll has surpassed 100,000,
and is the highest in Europe.

A third national lockdown in England is expected to run
until at least March as ministers try to bring a more contagious
variant of the virus under control. Scotland, Wales and Northern
Ireland, whose governments decide on their own measures, are
also living under tight restrictions.

AHEAD ON MANUFACTURING

The swiftest mass vaccination drive in history is stoking
tensions across the world as big powers buy up doses in bulk and
poorer nations try to navigate a financial and diplomatic
minefield to collect whatever supplies are left.

The United Kingdom has secured 367 million doses of the
seven most promising vaccines, including 100 million doses of
the AstraZeneca vaccine which was developed by Oxford
University.

Among those procured by Britain include a vaccine developed
by Novavax, which on Thursday said it proved 89%
effective in a UK trial, and Johnson & Johnson, which on Friday
said its shot was between 72% to 66% effective.

Kate Bingham, the former head of Britain's vaccine
taskforce, said the country had been able to secure supplies by
supporting pharmaceutical companies, setting up clinical trials
quickly and helping firms procure equipment to increase
manufacturing.

She declined to comment on the detail of the contract with
AstraZeneca but said the United Kingdom had benefited from early
work to be ready to make vaccines.

"That is ultimately the difference as to why we're so far
ahead on manufacturing," Bingham said, adding that she did not
expect the EU to block vaccine exports to the United Kingdom.

NO LONGER TENABLE

Scotland will publish COVID-19 detailed vaccine supply data
next week even though the British government has refused to do
so.

British prisons minister Lucy Frazer said the government
could not publish supply details for national security reasons,
which she declined to specify.

Scotland's health minister Jeane Freeman said that citing
national security was "not credible" because the British
government had repeatedly briefed statistics to reporters
showing how much vaccine Scotland had been allocated.

"We've held off publication in the past at their request.
But that's no longer tenable," she said at a news conference.

"The public have a right to clarity and we will give them
that. We're not talking about future supplies, we're talking
about known supplies."
(Reporting by Sarah Young, Alistair Smout and William James;
editing by Angus MacSwan)

More News
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more
3 Nov 2023 17:06

AstraZeneca plans next phase of trial on kidney drug combination data

(Alliance News) - AstraZeneca PLC on Friday touted results from a Phase IIb trial, which showed that a zibotentan and dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria.

Read more
3 Nov 2023 11:34

AstraZeneca's Lokelma lets kidney disease patients maintain therapy

(Alliance News) - AstraZeneca PLC on Thursday celebrated results from an observational study, which showed that treating hyperkalaemia with the potassium binder, Lokelma, allows chronic kidney disease and heart failure patients to maintain RAASi therapy.

Read more
2 Nov 2023 15:57

UK earnings, trading statements calendar - next 7 days

Friday 3 November 
no events scheduled 
Monday 6 November 
Kingspan Group PLCTrading Statement
Kosmos Energy LtdQ3 Results
Ryanair Holdings PLCHalf Year Results
Tuesday 7 November 
Associated British Foods PLCFull Year Results
Beazley PLCQ3 Results
Direct Line Insurance Group PLCTrading Statement
dotdigital Group PLCFull Year Results
IWG PLCQ3 Results
Persimmon PLCTrading Statement
RS Group PLCHalf Year Results
Vaalco Energy IncQ3 Results
Watches of Switzerland Group PLCTrading Statement
Wednesday 8 November 
Conduit Holdings LtdQ3 Results
ITV PLCTrading Statement
JD Wetherspoon PLCQ1 Results
Marks & Spencer Group PLCHalf Year Results
MaxCyte IncQ3 Results
Secure Trust Bank PLCTrading Statement
Smiths News PLCFull Year Results
Time Out Group PLCFull Year Results
Thursday 9 November 
3i Group PLCHalf Year Results
Apax Global Alpha LtdQ3 Results
AstraZeneca PLCQ3 Results
Auto Trader Group PLCHalf Year Results
B&M European Value Retail SAHalf Year Results
Domino's Pizza Group PLCTrading Statement
Endeavour Mining PLCQ3 Results
Flutter Entertainment PLCTrading Statement
IMI PLCTrading Statement
Indivior PLCQ3 Results
John Wood Group PLCTrading Statement
Lancashire Holdings LtdTrading Statement
National Grid PLCHalf Year Results
Regional REIT LtdTrading Statement
Renewi PLCHalf Year Results
S4 Capital PLCTrading Statement
Tate & Lyle PLCHalf Year Results
Taylor Wimpey PLCTrading Statement
TBC Bank Group PLCQ3 Results
TheWorks.co.uk PLCTrading Statement
Trakm8 Holdings PLCHalf Year Results
Urban Logistics REIT PLCHalf Year Results
Vistry Group PLCTrading Statement
WH Smith PLCFull Year Results
Wincanton PLCHalf Year Results
Wizz Air Holdings PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
1 Nov 2023 08:59

AstraZeneca launches collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Wednesday announced a new collaboration and investment agreement with clinical-stage biotechnology company Cellectis.

Read more
1 Nov 2023 07:33

AstraZeneca invests $220m in French gene-editing group Cellectis

(Sharecast News) - AstraZeneca is to invest in French biopharma group Cellectis to use its gene-editing technologies to develop next-gen therapeutics in areas like oncology, immunology and rare diseases.

Read more
30 Oct 2023 09:40

LONDON BROKER RATINGS: Jefferies cuts NatWest to underperform from buy

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
25 Oct 2023 11:04

PRESS: Soriot commits to five more years as AstraZeneca CEO - Times

(Alliance News) - Pascal Soriot has committed to remaining as chief executive officer of AstraZeneca PLC for another five years, The Times reported on Wednesday.

Read more
24 Oct 2023 17:08

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

Read more
24 Oct 2023 11:06

AstraZeneca says US accepts self-administered flu vaccine for review

(Alliance News) - AstraZeneca PLC on Tuesday said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine, for which the drugmaker is seeking a green light.

Read more
23 Oct 2023 17:50

AstraZeneca celebrates drug trial results for cancer indications

(Alliance News) - AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive results in patients with solid tumours, lung and breast cancer.

Read more
23 Oct 2023 17:08

LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities

(Alliance News) - Stock prices in London closed largely lower on Monday, as investors were unable to shake off concerns surrounding the conflict in the Middle East, while developments in the US bond market added to the drama.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.